Sanofi's Amlitelimab Shows Promise in Atopic Dermatitis Treatment

Sanofi’s amlitelimab has demonstrated significant potential in treating atopic dermatitis according to recent results from its SHORE and COAST 2 phase 3 studies. Amlitelimab achieved primary and key secondary endpoints at Week 24 with increasing efficacy throughout the treatment period in the SHORE study. In COAST 2, significant primary endpoint efficacy was noted for US and reference countries, though not for EU countries.

Given the comprehensive data, Sanofi plans global regulatory submissions for amlitelimab. The ATLANTIS phase 2 study also showed ongoing improvement through Week 52, underscoring OX40-ligand's potential as a novel mechanism in atopic dermatitis treatment.

Throughout the studies, amlitelimab was generally well-tolerated, with adverse events comparable to placebo. These findings bolster the confidence in amlitelimab’s potential to enhance treatment outcomes for patients with moderate-to-severe atopic dermatitis.